ArticleFrontiers in pharmacology2026
Regulation on the metabolic synaptic pathway in the dorsal raphe nucleus in a rat model chronic olanzapine-induced body weight gain.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the proteomic difference and mechanism in the dorsal raphe nucleus (DRN) of rats with body weight gain induced by long-term olanzapine administration. Methods: Thirty-six female Sprague-Dawley rats were randomly divided into two groups: an olanzapine treatment group (2.4 mg/(kg·d) and a vehicle control group (0.5% sodium carboxymethyl cellulose). Both treatments were administrated via drinking water for 24 continuous weeks. On the last day of 24th week, DRN samples were collected for proteomic analysis, quantitative real-time reverse transcription polymerase chain reaction (qPCR), Western blot (WB) analysis and bioassays. Differentially expressed proteins related to olanzapine treatment were subjected to bioinformatics analysis. Target genes were selected based on proteomic data for validation using qPCR and WB. Oxidative stress and inflammatory reaction were performed. Results: Body weight gain in the olanzapine group was significantly higher than in the control group starting from the week 18, exceeding 10% by week 24. Proteomic analysis identified 156 upregulated and 37 downregulated proteins in the DRN of the olanzapine-treated rats compared to the controls. KEGG analysis enriched these differentially expressed proteins into serotonergic, glutamatergic, and GABAergic synapses, alongside calcium signaling pathways related to olanzapine treatment. Protein-protein interaction (PPI) network analysis indicated that several olanzapine-associated differentially expressed proteins, including Ddc, Gchfr, Chrnb2, Tph2, Gad1, Grm1, Slc17a7, Gabra2, Gabra4, Gng3, Gng13, and Gnb4, were closely correlated to metabolic disorders. qPCR and WB confirmed that Tph2, the rate-limiting enzyme for 5-HT biosynthesis were significantly downregulated in the DRN of the olanzapine-treated rats ( Conclusion: Long-term olanzapine treatment induces significant body weight gain in female rats. This metabolic dysregulation is associated with alterations in multiple central pathways within the DRN, including the 5-HT synaptic signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.